Two new analyses of the pivotal Phase 3 PRECISION study suggest the drug aprocitentan delivers rapid, double-digit blood-pressure reductions in patients with resistant hypertension, Swiss drugmaker Idorsia said on Monday.
The findings, presented at the American Heart Association’s Hypertension Scientific Sessions 2026 on October 10, focused on two groups with notoriously difficult-to-control hypertension: patients with obesity and patients across the cardiovascular-kidney-metabolic continuum. In both groups, aprocitentan produced fast and pronounced blood-pressure drops, alongside improved kidney markers and stable renal function — a possible sign of kidney protection.
Aprocitentan works by blocking the endothelin pathway, a hormonal system that tightens blood vessels and raises blood pressure. In resistant hypertension, that system is often overactive, which is why the drug’s developer argues it addresses a root mechanism rather than just a symptom. Read the study announcement.
Why resistant hypertension is hard to treat
Resistant hypertension — blood pressure that stays high despite multiple medications — raises the risk of heart attack, stroke and kidney failure, and it is becoming more common as obesity rates climb. Standard drugs often fail these patients because overlapping metabolic problems keep pushing blood pressure upward.
That is what makes the obesity subgroup results notable: the drug produced consistent reductions even in patients whose complex, overlapping risks usually blunt treatment effects. Public-health researchers are increasingly focused on how age and metabolic patterns shape disease risk.
What experts will be watching
Cautious notes apply: these are company-reported analyses from a sponsored trial, and the full peer-reviewed publication is still pending. Independent cardiologists will want to see the complete safety data and how the benefits hold up over longer follow-up before judging the drug’s place in treatment guidelines.
Still, for the millions living with blood pressure that resists current medicines, a new mechanism of action is genuinely welcome news. How new treatments are tested remains under close ethical scrutiny.
